Treg EVs

Treg EVs are extracellular vesicles (EVs) derived from regulatory T cells (Tregs), a specialized subset of immune cells known for their immunosuppressive properties. These vesicles are small membrane-bound particles released by activated human or murine Tregs and contain proteins, surface markers (such as CD25 and CD39), and nucleic acids including miRNAs. Mechanistically, Treg EVs suppress effector T cell proliferation, modulate cytokine production toward anti-inflammatory profiles (increasing IL-4 and IL-10), inhibit cytotoxic CD8+ responses, modify antigen-presenting cells to a more tolerogenic phenotype via miRNA transfer (e.g., Let-7d to Th1 cells; miR-150-p/miR-142-3p to dendritic cells), and promote adenosine-mediated immunosuppression through CD73 activity. In preclinical models such as humanized mouse skin transplantation, administration of human Treg EVs protected graft tissue from alloimmune damage. The therapeutic potential of these vesicles is being explored for preventing transplant rejection and treating autoimmune diseases by inducing immune tolerance[1][4]. There is ongoing research into engineering "designer" or antigen-specific versions for enhanced efficacy.

Other names

regulatory T cell extracellular vesiclesTreg-derived extracellular vesiclesTreg-derived sEVs